Veradermics, Inc
corporate_fare Company Profile
Veradermics, Inc (NYSE:MANE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for MANE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MANE spans 4, 10-Q, 8-K, SCHEDULE 13D/A.
Recent high-impact activity:
- Veradermics Director Enright Sells $75.2M in Stock at $150.38
- Veradermics 10-Q: $798.4M Cash Into 2030, Q3 Loss $21.0M, New 10b5-1 Plans
- Veradermics Posts $21.0M Q3 Loss, $798.4M Cash Funds Operations Into 2030
- Veradermics' Oral Hair-Loss Pill Deepens Hair Count at 12 Months in Phase 3 Study
- Veradermics Sets Nov. 9 Call to Unveil 12-Month Phase 3 '302' Hair Loss Data
Financial Snapshot
Short Interest & Short Volume
5.06 days to coverFINRA reported short interest of 3,389,250 shares in MANE as of the October 30, 2026 settlement, a 8.4% decrease from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 76.3% of MANE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for MANE, detected from its recent SEC filings.
Massive Resale Registration · No Proceeds to Company
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →